Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of add-on Therapy With Vildagliptin in Chinese Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with T2DM who have received metformin for at least 8 weeks and have been on a stable dose of at least 1500 mg daily for a minimum of 4 weeks prior to visit 1~* Agreement to maintain the same dose of metformin from randomization to the end of the study~* Age in the range of 18-78 years inclusive~* Body mass index (BMI) in the range of 20-40 kg/m2 inclusive at Visit 1~* HbA1c in the range of \> 7.0 to ≤10% at Visit 1~* Agreement to maintain prior diet and exercise habits during the full course of the study~* Ability to comply with all study requirements~Exclusion Criteria:~* Fasting Plasma Glucose (FPG) \> 270 mg/dl (15 mmol/L) at Visit 1~* Pregnant or nursing (lactating) women~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 78 Years
- Healthy Volunteers: f

Study Arms:
- Vildagliptin Dose 1 (Type: EXPERIMENTAL): None
- Vildagliptin Dose 2 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).